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Abstract Although atypical antipsychotics have been associated with improvements in cognitive function in
schizophrenia, the neurochemical basis for such effects is not well understood. Candidate neu-
rotransmitter systems primarily involve dopamine and serotonin. The current study explored this
issue by examining the cognitive abilities, social function and quality of life in patients with schizo-
phrenia who were medicated with atypical antipsychotics. Comparisons were done for matched
schizophrenia patients who were on antipsychotics with (i) an affinity for multiple receptors (olan-
zapine, clozapine, quetiapine) versus those that have preferential affinity for dopamine receptors
(risperidone, amisulpride); and patients on medication with (ii) a high affinity for serotonin (5HT-
2A) receptors (risperidone, olanzapine, clozapine) versus those with a low (or no) affinity for 5HT-
2A receptors (quetiapine, amisulpride). No differences emerged between groups on any cognitive
or social variable when the groups were compared for the dopaminergic properties of antipsychotic
medication. By contrast, differences did emerge when patients were compared on the 5HT-2A
affinity of their antipsychotic medications. Patients on low 5HT-2A-affinity antipsychotics exhib-
ited a better performance on a measure of selective attention and adjustment to living. These find-
ings accord with the notion that serotonergic mechanisms are important determinants of both the
cognitive and the social effects of the atypical antipsychotics.
Key words 5HT-2A, atypical antipsychotics, cognition, dopamine, schizophrenia, serotonin, social function.
INTRODUCTION
The emergence of the atypical antipsychotics as the
front-line treatment for schizophrenia has brought
more than just the hope that positive and negative
symptoms will be successfully treated. There is the
hope that the cognitive deficits, which are also a feature
of the disorder, may be addressed. Such deficits, com-
monly involving aspects of memory, attention and
executive function,1 can be a severe hindrance to the
quality of life and social/occupational functioning of
many patients.2–4
Studies have found that the most widely used atypi-
cal antipsychotics, olanzapine, clozapine, risperidone,
quetiapine and amisulpride, all have an influence on
cognitive function in schizophrenia, and this influence
is mostly a positive one.5–7 Nevertheless, it remains
unclear precisely how these medications exert their
cognitive effects, and an understanding of the biochem-
ical mechanisms involved remains an important goal
for researchers and clinicians alike. Candidate neu-
rotransmitter systems primarily include dopamine and
serotonin (5HT-2A).
Dopaminergic effects
The atypical antipsychotics all exert an influence on the
dopaminergic system, and it is well established that this
system plays a role in cognitive processes.8–14 It is there-
fore plausible that antipsychotic action at this neu-
rotransmitter site may underlie the cognitive effects of
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these medications. The influence of dopamine on cog-
nitive function is believed to be mediated by several
dopaminergic subtypes that are represented in the pre-
frontal cortex, including D1, D2, D4 and D5.15 The
atypical antipsychotics all have an antagonistic (block-
ing) effect on dopaminergic receptors, yet they differ in
their antagonistic potential (expressed as Ki nm).
While risperidone and amisulpride have strong affini-
ties (and hence greater antagonistic potential) for all
dopamine receptor subtypes (e.g. risperidone receptor
affinity for D2 is 3 Ki nm, amisulpride is 2.8 Ki nm),
clozapine, olanzapine and quetiapine do not. In con-
trast, the latter compounds have less affinity to dopam-
ine receptors (e.g. clozapine affinity for D2 receptors is
126 Ki nm; olanzapine, 112 Ki nm; quetiapine, 160 Ki
nm) and their antagonistic effects are much more wide-
spread: involving multiple receptor types.16–18 The dis-
tinction between the dopamine-focused antipsychotic
compounds and those that act on multiple receptors
provides the opportunity to contrast the cognitive
effects of these groups of medications. This will clarify
the contribution of the dopaminergic system in the cog-
nitive action of the atypical antipsychotics.
Serotonergic effects
Another potential mechanism of action for the cogni-
tive effects of the atypical antipsychotics is the seroton-
ergic system. Indeed, unequivocal evidence indicates
that serotonin plays an important role in cognitive
function and this influence mainly involves 5HT-2A
receptors, although other receptors may also play a
role.19,20 Some authors suggest that atypical antipsy-
chotics influence cognitive function by antagonizing
5HT-2A receptors, which leads to an increase in pre-
frontal dopamine turnover and a consequent improve-
ment of the cognitive functions that are mediated by
the prefrontal cortex.21
Studies with schizophrenia patient have also sup-
ported this hypothesis. Poyurovsky et al. gave 30
patients a daily dose of a drug that has 5HT-2A antag-
onist properties (mianserin) and found an improve-
ment on a neuropsychological battery after 4 weeks.22
Potkin et al. found that another 5HT-2A antagonist
(M100907) decreased errors on the Wisconsin Card
Sorting Test.23 Finally, a 5HT-2A agonist (psilocybin)
was found to impair performance on a continuous per-
formance test in healthy volunteers.24 The evidence
therefore suggests that 5HT-2A antagonism enhances
cognitive function, while agonism impairs it.
With regard to the atypical antipsychotics, these do
not exert a uniform effect on 5HT-2A receptors, rather,
they can be divided into two groups according to their
affinity to 5HT-2A receptors.25 Those that have a high
affinity for 5HT-2A (affinity constant: risperidone [0.6],
olanzapine [4], clozapine [12]) and those that have low
or no affinity for 5HT-2A (quetiapine [220], amisul-
pride [infinity]).26 If antagonism of 5HT-2A receptors
were an important determinant of the cognitive effects
of the atypical antipsychotics, then we would expect a
difference in cognitive function between patients tak-
ing high-5HT-2A-affinity antipsychotics and those tak-
ing low- or no-5HT-2A-affinity antipsychotics.
These two neurotransmitter systems therefore pro-
vide potential candidates to explain the cognitive
effects of the atypical antipsychotics. The ideal meth-
odology for exploring this issue is to do a longitudinal
follow-up study to track changes over time for patients
on their respective medications. These types of studies
are, however, prone to a number of extraneous prob-
lem variables such as patient drop-out, medication
changes and test–retest reliability issues for some cog-
nitive tests. Another approach that minimizes such
problems is to use cross-sectional methodology where
patients who are matched on demographic variables,
psychopathology and premorbid IQ are compared on
cognitive measures at a particular time point. This
approach is useful in providing a snapshot of cognitive
function in schizophrenia and how patients, on differ-
ent medication regimens, are fairing.
The aims of the current study are as follows.
(1) To compare the cognitive abilities, social function
and quality of life of patients with schizophrenia who
are on atypical antipsychotics that have (i) an affinity
for multiple receptors (olanzapine, clozapine, quetiap-
ine) versus those that have preferential affinity for
dopamine receptors (risperidone, amisulpride); and
(ii) a high affinity for 5HT-2A receptors (risperidone,
olanzapine, clozapine) versus those that have a low (or
no) affinity for 5HT-2A receptors (quetiapine, amisul-
pride). Small numbers precluded comparisons between
each individual medication group.
(2) To explore associations between the neurochem-
ical properties of the atypical antipsychotics and social
function and quality of life in schizophrenia.
METHODS
Patients
Thirty patients (25 male; five female) with a DSM-IV
diagnosis of schizophrenia, were recruited from inpa-
tient (n = 5) and outpatient (n = 25) units in East York-
shire, UK. All gave informed consent to participate in
the study. None of the patients had a history of neuro-
logical disease, head injury, substance or alcohol abuse.
The average age of the patients was 38 ± 7.8 years
(range 22–52 years), with a mean length of illness of
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12 ± 6 years (range, 2 months−25 years). Symptom type
and severity was assessed with the Brief Psychiatric
Scale (BPRS),27 which gave a mean total score of 10.2 ±
4.6 (range, 3–22). When the BPRS score was broken
down according to four symptom dimensions,28 the rat-
ings were: thinking disturbance, mean 3.6 ± 2.5, range
0–9; withdrawal/retardation, mean 1.8 ± 1.8, range 0–6;
hostility/suspiciousness, mean, 1.6 ± 1.4, range 0–4; and
anxiety/depression, mean 4.9 ± 3.0, range 1–12. The
National Adult Reading Test (NART29) was used to
assess premorbid IQ.
To investigate associations between medication
levels and neuropsychological test performance,
antipsychotic dosages were converted to the percent-
age of maximum dose (PMD) according to the British
National Formulary.30 This is a novel yet reliable
method of comparing antipsychotic potency and avoids
some of the problems of using chlorpromazine equiv-
alents as a method of investigating dose equivalence.31
Table 1 provides a summary of patient medication type
and dosage and mean PMD for each medication group.
Demographics with regard to dopamine, and 5HT-2A
affinity are given in Tables 2,3.
Procedure
Measures of cognitive function
The neurocognitive battery was chosen to provide a
comprehensive investigation of cognitive ability; short-
term memory, working memory, attention (sustained,
selective and divided) and executive function. Where
possible the emphasis was on tests with strong ecologic
validity.
Table 1. Medication summary
Antipsychotic n






Olanzapine 8 12 62 25
Risperidone 5 4 25 24
Clozapine 8 350 38 44
Quetiapine 5 350 46 26
Amisulpride 4 500 41 8
Table 2. Group split according to dopamine
Multiple receptor group Preferential dopamine group P
Age (years) 39.19 35.77 0.28
Premorbid IQ 98.19 98.55 0.95
Length of illness (months) 159.52 117.33 0.17
Months on medication 32.81 17.55 0.08
% max dose 49.38 33.61 0.08
BPRS total score 10.14 10.44 0.88
BPRS, Brief Psychiatric Rating Scale.
Table 3. Group split according to 5HT-2A
High affinity Low affinity P
Age (years) 37.47 39.77 0.47
Premorbid IQ 94.91 106.22 0.05
Length of illness (months) 141.81 158.66 0.56
Months on medication 32.43 18.44 0.11
% max dose 44.92 44.00 0.92
BPRS total score 10.19 10.33 0.94
BPRS, Brief Psychiatric Rating Scale; 5HT-2A, serotonin.
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Digit span. This test is considered to reflect short-
term verbal memory and requires a subject to repeat
an increasing sequence of numbers.32
Digit span reversed. This test uses the same proce-
dure as the digit span (DS) test except that the
sequence of numbers has to be repeated in reverse
order. This test requires the manipulation (reversal) of
items that are held in short-term working memory.32
Test of Everyday Attention. This battery of tests is
designed to measure attentional abilities in an every-
day setting using naturalistic tasks.33 Because it would
take a whole hour to administer the whole battery,
three subtests were chosen that we felt were represen-
tative of the key components of attention: (i) sustained
attention (this refers to the ability to sustain attention
to repetitive stimuli), the Test of Everyday Attention
(TEA) subtest that measured this ability involved
counting sequences of bleeps played on an audiotape;
(ii) selective attention (this refers to the ability to
attend to target stimuli in the presence of powerful dis-
tracters), this subtest involved counting bleeps of a cer-
tain pitch, while ignoring bleeps of a different pitch;
and (iii) divided attention (this concerns the ability to
respond to more than one task at the same time), the
TEA subtest of this ability involves an auditory count-
ing task and a visual search task that have to be per-
formed simultaneously.
Behavioral  Assessment  of  the  Dysexecutive  Syn-
drome. This battery of tests assesses executive skills
using naturalistic tasks, such as searching for a key,
planning a route around a zoo, and organizing several
tasks within a time limit.34 It is sensitive to problems
such as an inability to co-ordinate and guide lower
level processes such as memory and attention, the
planning, initiation and sequencing of behavior, and
the inhibition of behavior that is inconsistent with a
specific goal.
Other measures
Multinomah Community Ability Scale. This scale
is designed to measure the level of social functioning of
chronically mentally ill patients living in the commu-
nity.35 It is designed to be completed by someone with
a detailed knowledge of the patient and is based on a
likert scale scoring system. It poses questions about a
number of different domains of social function,
although an abridged version of this scale was used in
the current study which included the modules adjust-
ment to living (section 2, 3 questions) and social com-
petence (section 3, 5 items). For patients who were not
living in the community at the time of the study (5/30),
the staff member who completed the scale was asked to
judge the social abilities of the patients from what they
had observed on the unit, and what they knew about
how well the patient coped on home visits.
Quality of  Life Self-Assessment  Inventory. This
scale contains a 100-item inventory divided into 11
domains: housing, environment, knowledge and educa-
tion, contacts, dependence, inner experiences, mental
health, physical health, leisure, work, and religion.36
Patients are asked to circle the items that they judge
unsatisfactory at present (e.g. size of housing, friend-
ships). The higher the number of items circled, the
lower is judged their quality of life.
RESULTS
Student’s t-tests were used to compare the patients in
terms of the dopaminergic and serotonergic profile of
their antipsychotic medication. No differences
emerged on any of the demographic, neuropsycholog-
ical or social variables when the groups were compared
in terms of the dopaminergic properties of their antip-
sychotic medication. A single difference did emerge on
the BPRS Hostility/Suspiciousness dimension with the
preferential dopamine affinity group scoring higher
than the multiple receptor group (2.4 vs 1.2: t28 = −2.31,
P = 0.028).
By contrast, several differences in cognitive perfor-
mance emerged when the patients were split in terms
of the 5HT-2A affinity of their antipsychotic medica-
tions. The patients on low-5HT-2A-affinity antipsy-
chotics (amisulpride, quetiapine) achieved significantly
better scores on the digit span test, the TEA elevator
counting test and the TEA elevator counting with dis-
traction test. In addition, they also scored more highly
on the adjustment to living subscale from the Multi-
nomah questionnaire (Table 4).
Although the high- and low-affinity groups were
matched for age, duration of illness, number of months
on medication and symptom variables, the patients on
low-5HT-2A-affinity antipsychotics had significantly
greater IQ than the high-5HT-2A-affinity group (106 vs
95: t28 = −2.07, P = 0.047). To consider the possibility
that premorbid IQ differences could account for the
differences in cognitive and social performance, a
manova was performed with premorbid IQ as a cova-
riate. The group difference on the digit span test (P =
0.092) and the TEA elevator counting task (P = 0.13)
were no longer significant, although the group differ-
ences remained on the TEA elevator counting with dis-
traction test (P = 0.048), and the adjustment to living
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subscale of the Multinomah questionnaire (P = 0.035).
It is also important to note that universally the patients
on low-5HT-2A-affinity antipsychotics had higher
mean scores on all the cognitive and social variables
than the high-5HT-2A-affinity group. In addition, they
achieved a higher score on the quality of life measure,
indicative of a greater awareness of circumstantial
problems.
DISCUSSION
The current study reports that schizophrenic patients
taking atypical antipsychotics with little or no affinity
to 5HT-2A receptors (amisulpride, quetiapine) per-
formed better on a test of sustained attention and a
measure of social functioning than those on high-5HT-
2A-affinity antipsychotics (risperidone, olanzapine,
clozapine). In addition, a perusal of the mean scores on
each measure indicates a universally superior perfor-
mance of the low-5HT-2A-affinity group. By contrast,
splitting the patient group in terms of the dopaminergic
properties of the antipsychotics yielded no group dif-
ferences. These findings suggests that 5HT-2A affinity
plays an important role in the cognitive effects of the
atypical antipsychotics, and that low or no affinity is
more beneficial for cognition and social function than
high affinity.
At first glance this finding appears contradictory to
research suggesting that compounds with an antago-
nistic effect on 5HT-2A are beneficial for cognitive
function.22 If this were indeed the case then patients
medicated on compounds with the most antagonistic
potential for 5HT-2A receptors, would display
superior cognitive abilities than those who were on
medications with little or no antagonistic potential.
Nevertheless, the findings of the current study are
consistent with a recent report that found that over
an 18-month period, patients on low-5HT-2A-affinity
antipsychotics improved on measures of short-term
memory, recognition memory and thinking time on a
planning task.26 In contrast, patients on high-5HT-2A-
affinity antipsychotics had no change on measures of
digit span, but did suffer a decrement in perfor-
mance on recognition memory tests and thinking
time in a planning task (i.e. they became slower with
repeated testing). In addition, Wagner et al. reported
that the atypical antipsychotic amisulpride (which is
devoid of 5HT-2A affinity) was as effective at allevi-
ating cognitive deficits as olanzapine (high 5HT-2A
affinity).5 Although this finding in itself does not sug-
gest a cognitive advantage of atypical antipsychotics
with no affinity for 5HT-2A receptors, Wagner et al.
did note stronger effects of amisulpride on attention
and executive function and suggested that a similar
study with higher statistical power might demon-
strate an advantage of amisulpride over risperidone.5
Certainly, the assertion that serotonin activation
impairs learning and memory whereas reduced sero-
tonergic function enhances these processes needs
reconsideration.37
In addition, our finding of enhanced social abilities
for the low-5HT-2A-affinity group suggests that sero-
tonergic mechanisms are important for successful func-
tioning in a social environment. However, it is likely
that these superior social abilities are reflective of the
cognitive differences between groups, because we
found significant associations between several of our
measures of cognitive function and social abilities. In
addition, the link between cognition and social func-
tioning is well-established in the literature.2
1
Table 4. Cognitive and social measures according to 5HT-2A affinity (mean ± SD)
Domain of function Test/measure




(n = 9) t P
Effect
size (d)
Short-term memory Digit span forward 5.5 ± 1.0 6.5 ± 0.8 −2.49 0.02 1.02
Working memory Digit span backward 4.0 ± 1.1 4.6 ± 1.9 −1.16 0.25 0.48
Sustained attention TEA Elevator counting 5.4 ± 1.9 6.7 ± 0.6 −2.82 0.01 1.16
Selective attention TEA Elevator counting with distraction 4.0 ± 2.7 7.0 ± 2.5 −2.75 0.01 1.13
Divided attention Telephone search while counting 7.2 ± 12.0 6.3 ± 9.8 0.19 0.84 0.08
Executive function BADS total score 15.0 ± 3.6 15.8 ± 2.0 −0.64 0.52 0.26
Quality of life Self-assessment inventory 11.7 ± 9.5 17.2 ± 12.1 −1.28 0.21 0.53
Social function Multinomah scale total 27.9 ± 7.1 31.1 ± 5.0 −1.21 0.23 0.49
Multinomah scale adjustment to living 11.5 ± 3.1 13.8 ± 1.2 −2.87 0.01 1.18
Multinomah scale social competence 16.3 ± 4.4 17.2 ± 4.2 −0.50 0.62 0.20
BADS, Behavioural Assessment of the Dysexecutive Syndrome; 5HT-2A, serotonin; TEA, Test of Everyday Attention.
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Clearly, our findings can be considered only tenta-
tive at this stage because it remains difficult to precisely
define the neurochemical basis for the cognitive effects
of the atypical antipsychotics. Part of the problem
stems from the fact that the atypical antipsychotics act
on a number of neurotransmitters simultaneously, and
so they may exert a combined effect on the brain and
behavior that is not seen in more selective compounds,
such as those used in animal studies. Indeed, the role of
serotonergic–cholinergic interactions in the mediation
of cognitive behavior has been considered,20,38 as have
the interactions between norepinephrine, dopamine,
serotonin and the cholinergic system.19,39,40 In addition,
all the atypical antipsychotics except amisulpride exert
sedative side-effects,41 and these must be considered in
the light of their purported cognitive effects.
Furthermore, paradigmatic differences between
studies further limit the general conclusions that can be
drawn from this issue. These include the serotonin-
altering compound (global manipulation/depletion or
specific subtype manipulation/depletion); temporal
factors in compound administration (before, during or
after testing); the type of subject (rat, patient, or
healthy control); the cognitive tests administered
(which are rarely the same across studies); and the
length of the study.
One limitation of this study relates to its cross-
sectional rather than longitudinal design. Because we
did not take baseline measures on all variables, the
equivalence of the groups was not established. It is
therefore possible that the group differences we
observed were related to baseline differences rather
than medication differences. We do not, however, feel
that this is the case because the groups were matched
on a variety of relevant variables including: age, dura-
tion of illness, number of months on medication, per-
centage of maximum dose of medication and symptom
variables. The patients were also from similar socioeco-
nomic backgrounds. We did find a difference in pre-
morbid IQ between groups, but this was controlled in
analyses. We therefore make the assumption that the
groups were equivalent at baseline because they did
not differ on any variables that could have had an influ-
ence on their cognitive status. In conclusion, our study
findings accord with the wider literature indicating that
serotonergic mechanisms are important determinants
of the cognitive and social effects of the atypical
antipsychotics.
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